0001144204-11-033904.txt : 20110603 0001144204-11-033904.hdr.sgml : 20110603 20110603160651 ACCESSION NUMBER: 0001144204-11-033904 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110601 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20110603 DATE AS OF CHANGE: 20110603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 11892321 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 8-K 1 v224986_8k.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
 
Date of Report
(Date of earliest event reported): June 1, 2011
 
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)

Delaware
001-15281
76-0233274
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
2408 Timberloch Place, Suite B-7
The Woodlands, Texas  77380
(Address of principal
executive offices
and zip code)
 
(281) 719-3400
(Registrant’s telephone number, including area code)
  


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 5.07  Submission of Matters to a Vote of Security Holders.
 
Repros Therapeutics Inc. (the “Company”) held its 2011 Annual Meeting of Stockholders on June 1, 2011 in The Woodlands, Texas.  At the meeting, the Company’s stockholders: (i) elected each of the five persons listed below under Proposal 1 to serve as a director of the Company until its 2012 Annual Meeting of Stockholders; (ii) ratified and approved the appointment of PricewaterhouseCoopers LLP as the Company's registered independent public accounting firm for the Company's fiscal year ending December 31, 2011 and (iii) approved the proposal to approve and adopt the 2011 Equity Incentive Plan which provides for the grant of rights to purchase up to 2,000,000 shares of common stock of the Company.  The following table describes the results of the voting at the annual meeting:
 
Proposal or Name of Nominee
Shares Voted "For"
Shares Voted "Against"
Shares Withheld
Shares Abstained
Broker Non-Votes
Proposal 1: Election of Directors
          
Joseph S. Podolski
3,400,617
--
1,045,125
--
6,959,778
Daniel F. Cain
3,400,434
--
1,045,308
--
6,959,778
Jean L. Fourcroy, M.D., Ph.D.
3,400,912
--
1,044,830
--
6,959,778
Nola Masterson, M.S.
3,400,611
--
1,045,131
--
6,959,778
Jaye Thompson, Ph.D.
3,401,411
--
1,044,331
--
6,959,778
           
Proposal 2: Ratification of Appointment of PricewaterhouseCoopers LLP
10,330,241
10,499
--
1,064,780
--
           
Proposal 3:  Approval of 2011 Equity Incentive Plan
3,296,800
105,817
--
1,043,125
6,959,778
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  Repros Therapeutics Inc.  
       
Date:  June 3, 2011      
       
 
By:
/s/ Katherine A. Anderson  
    Katherine A. Anderson  
    Chief Accounting Officer